Cytosorbents Corporation (CTSO) News
Filter CTSO News Items
CTSO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTSO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CTSO News From Around the Web
Below are the latest news stories about CYTOSORBENTS CORP that investors may wish to consider to help them evaluate CTSO as an investment opportunity.
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in DubaiPRINCETON, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates (UAE). The new subsidiary provides a gateway into the Middle East and Africa - regions with increasing demand for advanced medical technologies and high-quality therapies in critical c |
CytoSorbents reported strong Q4 results, says D. Boral CapitalD. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents’ strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shar |
CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4 th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% growth compared to $7.35 million |
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product RevenueFourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced pre |
CytoSorbents Rights Offering BeginsTo Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025PRINCETON, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement press release. Stockholders and certain Warrantholders of record on December 16, 2024 are now being distributed a dividend of one non-transferable Sub |
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference WeekPRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-15, 2025, in San Francisco, CA. ICR Healthcare is coordinating meetings on the Company’s behalf. To schedule |
CTSO: CytoSorbents Announces Rights Offering Which has the Potential to Substantially Increase Available LiquidityBy Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own or have bought CTSO stock by the close of trading on Friday, December 13, 2024 will be considered stockholders of record on December 16, |
CytoSorbents Announces Rights OfferingInvestors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to ParticipatePRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the details of its anticipated Rights Offering. Investors who hold or have bought CTSO stock at the close of Nasdaq trading on Friday, December 13, |
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare ConferencePRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will participate at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY. Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, will participate in one-on-one inves |
CTSO: CytoSorbents Potential for High Margin Revenue Growth Supports Price Target of $4.00By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2024 results on November 7 th and the results came in above the company’s updated guidance provided on October 1 st . Total revenues increased approximately 6.6% to $9.4 million with product sales increasing 11.0% to $8.6 million. Product revenue guidance was in the $8.3-$8.5 million |